Kết quả tìm kiếm - Takuji Okusaka
- Đang hiển thị 1 - 20 kết quả của 95
- Chuyển đến trang tiếp theo
-
1
Immunotherapy for hepatocellular carcinoma: current status and future perspectives Bằng Takuji Okusaka, Masafumi Ikeda
Được phát hành 2018Revisão -
2
-
3
Phase II study of S-1 in patients with advanced biliary tract cancer Bằng Hideki Ueno, Takuji Okusaka, Masafumi Ikeda, Yoriko Takezako, Chigusa Morizane
Được phát hành 2004Artigo -
4
A National Survey to Systematically Identify Factors Associated With Oncologists’ Attitudes Toward End-of-Life Discussions: What Determines Timing of End-of-Life Discussions? Bằng Masanori Mori, Chikako Shimizu, Asao Ogawa, Takuji Okusaka, Saran Yoshida, Tatsuya Morita
Được phát hành 2015Artigo -
5
Chemotherapy for hepatocellular carcinoma: current status and future perspectives Bằng Masafumi Ikeda, Chigusa Morizane, Makoto Ueno, Takuji Okusaka, Hiroshi Ishii, Junji Furuse
Được phát hành 2017Revisão -
6
New developments in systemic therapy for advanced biliary tract cancer Bằng Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, Takuji Okusaka, Hiroshi Ishii, Junji Furuse
Được phát hành 2018Revisão -
7
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT) Bằng Junki Mizusawa, Chigusa Morizane, Takuji Okusaka, Hiroshi Katayama, Hiroshi Ishii, Haruhiko Fukuda, Junji Furuse
Được phát hành 2016Artigo -
8
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses Bằng Toshiyuki Tamai, Seiichi Hayato, Seiichiro Hojo, Takuya Suzuki, Takuji Okusaka, Kenji Ikeda, Hiromitsu Kumada
Được phát hành 2017Artigo -
9
-
10
Phase <scp>II</scp> study of <scp>FOLFIRINOX</scp> for chemotherapy‐naïve Japanese patients with metastatic pancreatic cancer Bằng Takuji Okusaka, Masafumi Ikeda, Akira Fukutomi, Tatsuya Ioka, Junji Furuse, Shinichi Ohkawa, Hiroyuki Isayama, Narikazu Boku
Được phát hành 2014Artigo -
11
-
12
-
13
-
14
Japanese phase I study of<scp>GC</scp>33, a humanized antibody against glypican‐3 for advanced hepatocellular carcinoma Bằng Masafumi Ikeda, Shinichi Ohkawa, Takuji Okusaka, Shuichi Mitsunaga, Satoshi Kobayashi, Chigusa Morizane, Ikue Suzuki, S. Yamamoto, Junji Furuse
Được phát hành 2014Artigo -
15
-
16
-
17
A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT) Bằng Kohei Nakachi, Masaru Konishi, Masafumi Ikeda, Junki Mizusawa, Junko Eba, Takuji Okusaka, Hiroshi Ishii, Haruhiko Fukuda, Junji Furuse
Được phát hành 2018Artigo -
18
-
19
Phase II Study of Gemcitabine Chemotherapy Alone for Locally Advanced Pancreatic Carcinoma: JCOG0506 Bằng Hiroshi Ishii, J. Furuse, Narikazu Boku, Takuji Okusaka, Masafumi Ikeda, S. Ohkawa, Akira Fukutomi, Yasuo Hamamoto, K. Nakamura, Hiroyuki Fukuda
Được phát hành 2010Artigo -
20
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies Bằng Tal Grenader, Stephen Nash, Yevgeni Plotkin, Junji Furuse, Nobumasa Mizuno, Takuji Okusaka, Harpreet Wasan, Juan W. Valle, John Bridgewater
Được phát hành 2015Artigo
Công cụ tìm kiếm:
Các môn học liên quan
Internal medicine
Medicine
Cancer
Oncology
Gastroenterology
Chemotherapy
Pancreatic cancer
Gemcitabine
Hepatocellular carcinoma
Pathology
Randomized controlled trial
Clinical endpoint
Adverse effect
Phases of clinical research
Confidence interval
Surgery
Clinical trial
Biology
Sorafenib
Hazard ratio
Colorectal cancer
Alternative medicine
Placebo
Biochemistry
Gene
Carcinoma
Regimen
Toxicity
Biliary tract cancer
Cisplatin